Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage 主要内容 Main Navigation
Randomized Controlled Trial
. 2011 Nov 15;184(10):1125-32.
doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18.

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study

Mario Castro1, Sameer Mathur, Frederick Hargreave, Louis-Philippe Boulet, Fang Xie, James Young, H Jeffrey Wilkins, Timothy Henkel, Parameswaran Nair, Res-5-0010 Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study

Mario Castroet al. Am J Respir Crit Care Med. .

Abstract

Rationale:Eosinophilic asthma is a phenotype of asthma characterized by the persistence of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils.

Objectives:To evaluate the effect of the antibody to IL-5, reslizumab, in patients with eosinophilic asthma that is poorly controlled with high-dose inhaled corticosteroid.

Methods:Patients were randomly assigned to receive infusions of reslizumab at 3.0 mg/kg (n = 53) or placebo (n = 53) at baseline and at Weeks 4, 8, and 12, with stratification by baseline Asthma Control Questionnaire (ACQ) score less than or equal to 2 or greater than 2. The primary efficacy measure was the difference between the reslizumab and placebo groups in the change in ACQ score from baseline to end of therapy (Week 15 or early withdrawal).

Measurements and main results:Mean changes from baseline to end of therapy in ACQ score were -0.7 in the reslizumab group and -0.3 in the placebo group (P = 0.054) and in FEV(1) were 0.18 and -0.08 L, respectively (P = 0.002). In those patients with nasal polyps, the changes in ACQ score were -1.0 and -0.1, respectively (P = 0.012). Median percentage reductions from baseline in sputum eosinophils were 95.4 and 38.7%, respectively (P = 0.007). Eight percent of patients in the reslizumab group and 19% of patients in the placebo group had an asthma exacerbation (P = 0.083). The most common adverse events with reslizumab were nasopharyngitis, fatigue, and pharyngolaryngeal pain.

Conclusions:Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo. Reslizumab was generally well tolerated.

Comment in

Similar articles

看到所有类似的文章

Cited by

  • Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells.
    Chen S, Chen G, Xu F, Sun B, Chen X, Hu W, Li F, Syeda MZ, Chen H, Wu Y, Wu P, Jing R, Geng X, Zhang L, Tang L, Li W, Chen Z, Zhang C, Sun J, Chen W, Shen H, Ying S. Chen S, et al. Cell Discov. 2022 Aug 16;8(1):80. doi: 10.1038/s41421-022-00433-y. 细胞。2022。 PMID:35973984 Free PMC article.
  • Type 2 inflammation in asthma and other airway diseases.
    Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, Lababidi H, Ledanois O, Mahoub B, Perng DW, Vazquez JC, Yorgancioglu A. Maspero J, et al. ERJ Open Res. 2022 Aug 1;8(3):00576-2021. doi: 10.1183/23120541.00576-2021. eCollection 2022 Jul. ERJ Open Res. 2022. PMID:35923421 Free PMC article. Review.
  • Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.
    Porpodis K, Tsiouprou I, Apostolopoulos A, Ntontsi P, Fouka E, Papakosta D, Vliagoftis H, Domvri K. Porpodis K, et al. J Pers Med. 2022 Jun 30;12(7):1093. doi: 10.3390/jpm12071093. J Pers Med. 2022. PMID:35887589 Free PMC article. Review.
  • Anti-IL-5 therapies for asthma.
    Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Farne HA, et al. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4. Cochrane Database Syst Rev. 2022. PMID:35838542 Review.
  • Novel Biological Therapies for Severe Asthma Endotypes.
    Pelaia C, Pelaia G, Crimi C, Maglio A, Stanziola AA, Calabrese C, Terracciano R, Longhini F, Vatrella A. Pelaia C, et al. Biomedicines. 2022 May 4;10(5):1064. doi: 10.3390/biomedicines10051064. Biomedicines. 2022. PMID:35625801 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

Substances